kentucky semaglutide digestive blockage law office glp-1 gastrointestinal obstruction legal team in Zepbound Lawsuit [2026] semaglutide gastric intestinal obstruction law

Specific interference by ingested dsRNA

Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs

2) Study population: patients with T2DM and being overweight/obese

doi: 10.1007/s40263-018-0593-6